American Thoracic Society (ATS) 2024

The clinical and socioeconomic burden of bronchiectasis: results of a systematic literature review

Predictors of mortality in idiopathic pulmonary fibrosis: forced vital capacity decline and other surrogate endpoints – a literature review

Staying in the flow: preferential PDE4B inhibitor nerandomilast (BI 1015550) improves features of vascular dysfunction in lung fibrosis in vitro and in vivo

Baseline characteristics of patients enrolled in FIBRONEER™-IPF, a Phase III randomized placebo-controlled trial of the preferential PDE4B inhibitor nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis

Respiratory-related hospitalization and mechanical ventilation in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Mass spectrometry-based proteomics to evaluate the circulating proteome in idiopathic pulmonary fibrosis